Eikon Therapeutics, Inc. (EIKN)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004
Eikon Therapeutics NASDAQ: EIKN outlined its development strategy for selective PARP1 inhibitors and its Werner helicase inhibitor during a discussion hosted by Cantor biotech analyst Imogen Mansfield. President, Chief Executive Officer and Board Chair Roger Perlmutter and MD Anderson Cancer Center's Vice President and Head of Clinical Development Tim Yap discussed the rationale for improving on earlier PARP inhibitor therapies, which commonly inhibit both PARP1 and PARP2.
Eikon Therapeutics, Inc. (EIKN) Discusses Advances in PARP1 Biology and Next-Generation PARP Inhibitors in Oncology Transcript
Eikon Therapeutics, Inc. (EIKN) Discusses Advances in PARP1 Biology and Next-Generation PARP Inhibitors in Oncology Transcript
Eikon Therapeutics: Initiating Coverage With A Cautious Buy Rating
Eikon Therapeutics is initiated with a cautious buy, leveraging industry-leading management and a robust oncology-focused pipeline. EIKN's ASCO data for EIK1001 in NSCLC showed a 63.1% ORR and favorable safety, but the market response was muted. Cash reserves of $596m provide a runway into 2027 despite high R&D burn; valuation is now below cash, reflecting skepticism.
Eikon Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 John H. Burbank III Passport Capital LLC | 555,555 | $5.88M | $6.14M | $261,110.74 | 4.44% |
 Joseph Castro Nuveen LLC | 28,988 | $378,293 | $282,053.24 | -$96,239.76 | -25.44% |
 Ellen York T. Rowe Price Investment Management Inc. | 1.6M | $17.68M | $17.63M | -$55,441.14 | -0.31% |
 Regan O'Neill Burkehill Global Management LP | 115,000 | $1.22M | $1.27M | $54,050 | 4.44% |
 Drew Phillips Fortitude Family Office LLC | 121 | $1,579 | $1,114.41 | -$464.59 | -29.42% |
Eikon Therapeutics, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Robert Driscoll Wedbush | -2,412.16 | $27,788.13 | $25,231.24 | $2,556.89 | 9.2% |
Eikon Therapeutics, Inc. (EIKN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Eikon Therapeutics, Inc. ever had a stock split?
Eikon Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Roger Perlmutter CEO | NASDAQ (NMS) Exchange | 282564103 CUSIP |
| US Country | 384 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company operating in the United States, focused on developing innovative medicines that address serious unmet medical needs. Founded in 2019 and headquartered in Millbrae, California, Eikon Therapeutics is dedicated to advancing healthcare through discovery and innovation. The company's unique platform allows for precise characterization of protein interactions within living cells, which plays a crucial role in the identification and development of targeted therapies.
Products and Services
- EIK1001: A systemically administered TLR 7/8 dual-agonist designed to activate both innate and adaptive immune anti-tumor responses. This innovative approach aims to enhance the body’s natural ability to fight tumors.
- EIK1003: A selective PARP1 inhibitor that intends to target ovarian and breast cancers, among others. By focusing on specific cancer types, EIK1003 offers a tailored therapeutic approach to enhance treatment efficacy.
- EIK1004: Another selective PARP1 inhibitor, particularly notable for its brain-penetrant characteristics. This product is developed to address challenges posed by brain metastases and primary brain malignancies, expanding therapeutic options for patients with central nervous system involvement.
- EIK1005: A potent WRN helicase inhibitor designed as an anti-tumor agent for MSI-high tumors. EIK1005 focuses on exploiting the unique vulnerabilities of these tumors to provide a more effective treatment option.
- EIK1006: Further details on this product are yet to be disclosed. However, it represents Eikon Therapeutics' ongoing commitment to developing a diverse range of therapeutic agents targeting various cancers.
